Complex Generic Products Portfolio
Not Specified
Not SpecifiedActive
Key Facts
About Harvest Moon Pharmaceuticals USA
Harvest Moon Pharmaceuticals USA is a private, commercial-stage company specializing in complex generics and biosimilars, with a legacy pipeline acquired from TCI Generics. It operates a development and manufacturing model aimed at out-licensing products to partners worldwide, supported by an international sales force via PanGenerika B.V. The company's strategy targets the high-value, difficult-to-manufacture segment of the generic drug market to provide lower-cost alternatives to branded biologics and complex therapeutics.
View full company profileOther Not Specified Drugs
| Drug | Company | Phase |
|---|---|---|
| FL116 | Forlong Biotechnology | Not specified |
| FL117 | Forlong Biotechnology | Not specified |
| FL118 | Forlong Biotechnology | Not specified |
| FL301 | Forlong Biotechnology | Not specified |
| JSKN016 | AlphaMab Oncology | Phase 1 |
| JSKN033 | AlphaMab Oncology | Phase 1 |
| JSKN022 | AlphaMab Oncology | Phase 1 |
| JSKN027 | AlphaMab Oncology | Phase 1 |
| KN019 | AlphaMab Oncology | Phase 1 |
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| SR2162 | SIMR (Australia) Biotech | IND Approved |